Our major objective is to demonstrate that heart wall motion abnormalities characterized by early shortening/late lengthening trigger in the epicardium, local inflammation, reactive oxygen species generation, matrix metalloproteinase (MMP) activation and fibrillar collagen degradation leading to adverse chamber remodeling. Wall motion abnormalities secondary to dysynchronous contraction of the left ventricle (LV) as seen in heart failure reduce ejection fraction and promote remodeling. Similar changes occur in animal models of anterior LV wall epicardial pacing whereby adverse remodeling is characterized by thinning at the pacing site and hypertrophy of the posterior wall. Local strain patterns demonstrate early shortening and late systolic lengthening in the early activated areas (anterior wall) and early lengthening and subsequent shortening of the posterior wall. Preliminary data indicates that anterior wall pacing yields localized evidence for epicardial leucocyte (likely neutrophil) mediated inflammation, activation of MMPs, reactive oxygen species generation (ROS) and collagen degradation. We propose that the mechanism responsible for inflammation/injury is the local expression of adhesion molecules in the microvasculature secondary to alterations in coronary venule blood flow patterns.
Four aims are proposed.
Aim 1 will test the hypothesis that pacing induced early shortening leads to the local expression of adhesion molecules in coronary venules, trapping of leucocytes, generation of ROS, pro-MMP activation and fibrillar collagen degradation in the epicardium.
Aim 2 will test the hypothesis that early shortening regions of the LV demonstrate abnormal epicardial systolic tissue volume changes and modified patterns of epicardial venular blood flow.
Aim 3 will test the hypothesis that leucocyte generated ROS structurally modifies pro-MMP-9 in vitro and in vivo.
Aim 4 will test the hypothesis that long- term LV wall motion abnormalities induce adverse chamber remodeling characterized by epicardial wall thinning in areas associated with early shortening. A variety of cardiac mechanics, intravital microscopy, proteomics, biochemical and histological methods are to be used. Results from the proposed studies should aid in our understanding of how ventricular dysynchrony as seen in patients with heart failure and left bundle branch block leads to the development of adverse chamber remodeling and loss of contractile function. Anticipated outcome from the proposed studies may also aid clinicians in optimizing cardiac resynchronization therapy.

Public Health Relevance

The proposed research addresses an important clinical problem related to how, when the heart does not contract in unison it develops structural and functional abnormalities that are detrimental in nature. These abnormalities are frequently seen in patients with heart failure and our observations indicate that an underlying inflammatory process may explain these adverse changes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
3R01HL043617-15S1
Application #
7864685
Study Section
Special Emphasis Panel (ZRG1-CVS-P (02))
Program Officer
Wang, Lan-Hsiang
Project Start
1989-07-01
Project End
2012-03-31
Budget Start
2009-09-01
Budget End
2010-03-31
Support Year
15
Fiscal Year
2009
Total Cost
$35,308
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Moreno-Ulloa, Aldo; Nogueira, Leonardo; Rodriguez, Alonso et al. (2015) Recovery of Indicators of Mitochondrial Biogenesis, Oxidative Stress, and Aging With (-)-Epicatechin in Senile Mice. J Gerontol A Biol Sci Med Sci 70:1370-8
DeCoux, Ashley; Lindsey, Merry L; Villarreal, Francisco et al. (2014) Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol 77:64-72
Ortiz-Vilchis, Pilar; Yamazaki, Katrina Go; Rubio-Gayosso, Ivan et al. (2014) Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling. Eur J Pharmacol 744:76-82
Spinale, Francis G; Villarreal, Francisco (2014) Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol 90:7-15
Gutiérrez-Salmeán, Gabriela; Ortiz-Vilchis, Pilar; Vacaseydel, Claudia M et al. (2014) Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects. Food Funct 5:521-7
Gutierrez-Salmean, Gabriela; Ciaraldi, Theodore P; Nogueira, Leonardo et al. (2014) Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem 25:91-4
Aguilar, Hugo; Fricovsky, Eduardo; Ihm, Sang et al. (2014) Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. Am J Physiol Cell Physiol 306:C794-804
Moreno-Ulloa, Aldo; Romero-Perez, Diego; Villarreal, Francisco et al. (2014) Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor. Bioorg Med Chem Lett 24:2749-52
Yamazaki, Katrina Go; Andreyev, Aleksander Y; Ortiz-Vilchis, Pilar et al. (2014) Intravenous (-)-epicatechin reduces myocardial ischemic injury by protecting mitochondrial function. Int J Cardiol 175:297-306
Ramirez-Sanchez, Israel; De los Santos, Sergio; Gonzalez-Basurto, Silvia et al. (2014) (-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic ?-sarcoglycan null mouse striated muscle. FEBS J 281:5567-80

Showing the most recent 10 out of 61 publications